NASDAQ$TELA

TELA Bio Inc · Q4 2021 earnings

Q4 2021 earnings · · Investor relations

Briefing

TELA Bio reported financial results with revenue increase driven by commercial organization expansion and productivity gains.

TELA Bio reported a strong fourth quarter with a 48% increase in revenue compared to the prior year. The company's gross profit also increased, driven by a decrease in the reserve for excess and obsolete inventory. However, the company experienced a net loss of $8.6 million.

  • Revenue increased by 48% to $8.4 million compared to the prior year.
  • Gross profit increased to $5.7 million, representing 68% of revenue.
  • Operating expenses increased to $13.3 million due to expansion of commercialization activities.
  • Net loss was $8.6 million, compared to a net loss of $7.8 million in the same period in 2020.

Headline financials

Total Revenue

$8.37M

Previous: $5.67M+47.8%
EPS (adj)

-$0.59

Previous: -$0.54-9.3%
Capital Expenditures

$289K

Previous: $38K+660.5%
Free Cash Flow

-$9.88M

Previous: -$7.14M-38.3%
Net Income

-$8.6M

Previous: -$7.8M-10.3%
Operating Income

-$7.7M

Previous: -$6.7M-14.9%
Gross Profit

$5.7M

Previous: $3.7M+54.1%
Cash & Equivalents

$43.9M

Previous: $74.4M-41.0%
Total Assets

$62.5M

Previous: $86.5M-27.7%
Stock-Based Comp

$822K

Previous: $572K+43.7%

Revenue & EPS history

TELA Bio · Revenue · Quarterly

$8.37M

Q4 2021+47.8%vs Q4 2020
Beat estimate in 10 of 12 quarters(83%)
ActualEstimate

Forward guidance

Full year 2022 revenue is projected to range from $40 million to $45 million, reflecting growth of 36% to 53% over full year 2021.

Headwinds

  • The COVID-19 pandemic has had and will continue to have impact on our results of operations.
  • A higher than expected impact from the COVID-19 pandemic in 2022 could materially affect this projection.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 19 quarterly earnings reports · overlaid with Q4 2021

Historical avgQ4 2021

-2.5%

Avg return

Earnings day

-3.7%

Avg return

5 days after

+3.7%

Avg return

30 days after

42%

11 / 26 earnings

Positive

+20.2%

Q1 2024

Best reaction

-37.2%

Q4 2024

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026-5.3%-18.6%
Q4 2025+1.7%-25.8%-12.0%
Q3 2025-9.3%-2.7%+3.6%
Q1 2025+7.2%-0.1%+90.7%
Q4 2024-37.2%-44.9%-59.1%
Q3 2024+2.0%+3.0%-1.7%
Q2 2024-23.9%-23.4%-35.0%
Q1 2024+20.2%+21.2%+16.7%
Q4 2023+4.0%+0.9%-13.8%
Q3 2023-20.3%-21.7%-4.5%
Q2 2023-4.8%-1.2%-2.8%
Q1 2023-3.6%-4.8%+11.2%
Q4 2022-5.5%-3.7%-11.3%
Q3 2022+13.8%+11.2%+44.7%
Q2 2022-6.5%+5.5%+0.9%
Q1 2022-5.7%-7.0%-31.4%
Q4 2021-4.8%-4.8%-20.4%
Q3 2021-3.8%-3.7%-1.7%
Q2 2021+5.0%+4.4%-8.3%
Q1 2021+3.2%+11.5%+5.9%
Q4 2020-6.6%+0.9%-1.8%
Q3 2020-3.5%-0.8%-3.6%
Q2 2020+5.4%+4.1%+20.7%
Q1 2020-2.4%-3.6%+38.6%
Q4 2019+0.6%-0.4%+34.0%
Q3 2019+13.9%+8.8%+32.6%
Q2 2019
Q1 2019
Q4 2018
Q3 2018
Q2 2018
Q1 2018

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro